Insights Into Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL)
Perspectives of community physicians from across the US on the management of follicular lymphoma (FL) and marginal zone lymphoma (MZL)
Rocky Mountain Cancer Centers – June 17, 2021
Faculty Chair
John Burke, MD
Rocky Mountain Cancer Centers, Denver, CO
Southeast – June 21, 2021
Faculty Chair
Matthew Davids, MD
Dana-Farber Cancer Institute, Boston, MA
Baltimore/DC – October 6, 2021
Faculty Chair
John Burke, MD
Rocky Mountain Cancer Centers, Denver, CO
More Information
- Virtual Series
- Insights From Rocky Mountain Cancer Centers Physicians
More Information
- Virtual Series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Virtual Series
- Baltimore, Washington, D.C.
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of follicular lymphoma and marginal zone lymphoma
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights were obtained on the impact of second-line chemo-immunotherapies, anti-CD20 antibodies, PI3K inhibitors, bispecific antibodies, and CAR T therapy on patient management
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprised 10–15 medical oncologists representative of each region
